Low
₹52.90
High
₹56.85
| Previous Close | ₹53.20 |
|---|---|
| Day's Range | ₹52.90 - ₹56.85 |
| Open | ₹56.80 |
| 52 Week Range | ₹33.05 - ₹64.58 |
| Volume | 81,96,539 |
| Market Cap | ₹0.00 |
| Previous Close | ₹53.27 |
|---|---|
| Day's Range | ₹52.95 - ₹56.70 |
| Open | ₹56.70 |
| 52 Week Range | ₹33.44 - ₹64.57 |
| Volume | 6,76,524 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 4,437.82 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.38 |
| Price/Earning (TTM) | 30.77 |
| TTM EPS (₹) | 1.73 |
| P/E Ratio | 22.21 |
| Book Value(₹) | 2.34 |
| PAT Margin (%) | 6.51 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 15.48 |
| Trade Value ( ₹ in Lacs) | 365.43 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.38 |
| Price/Earning (TTM) | 30.77 |
| TTM EPS (₹) | 1.73 |
| P/E Ratio | 22.21 |
| Book Value(₹) | 2.34 |
| PAT Margin (%) | 6.51 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 15.48 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 3819.38 | 15545.35 |
| Expenses | N/A | N/A |
| PBT | 173.04 | 1375.86 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 119.11 | 1015.75 |
| Founded | 1984 |
|---|---|
| Managing Director | Sushil Suri |
| NSE Symbol | MOREPENLAB |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,178.79 | 1,942.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,095.00 | 7,386.75 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,91,530.43 | 5,042.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,516.16 | 8,940.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,318.19 | 1,417.10 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,12,693.00 | 1,129.75 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,001.57 | 2,408.50 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,274.12 | 1,083.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,068.24 | 2,550.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 98,742.15 | 1,183.00 | 1,148.40 - 1,148.40 |
No Records Found
Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Morepen Laboratories Ltd. is ₹53.20 as of 2026-07-22.
The market capitalisation of Morepen Laboratories Ltd. is ₹2,918.95 as of 2026-07-22.
The 1-year return of Morepen Laboratories Ltd. is -8.49% as of 2026-07-22.
The P/E ratio of Morepen Laboratories Ltd. is 22.21 as of 2026-07-23.
The 52-week high and low of Morepen Laboratories Ltd. are ₹64.58 and ₹33.05, respectively, as of 2026-07-22.
Morepen Laboratories Ltd. offers a broad healthcare portfolio that includes Active Pharmaceutical Ingredients (APIs) such as antihistamines and statins, as well as known branded OTC products like Burnol. Their offerings also extend to a diagnostics division that provides home-health devices, including digital glucose monitors and blood pressure monitors.
Morepen Laboratories Ltd. collaborates with pharmaceutical companies through the supply of Active Pharmaceutical Ingredients (APIs) and contract manufacturing services. The company also supplies diagnostic medical devices and point-of-care testing solutions that are used by hospitals, clinics and other healthcare providers for patient monitoring and diagnostic purposes.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.